Search

Your search keyword '"Laws, Philip M"' showing total 22 results
Start Over Author "Laws, Philip M"
22 results on '"Laws, Philip M"'

3. High prevalence of undiagnosed and undertreated psoriasis in a UK urban population: results from the observational COPPACA study.

Author

Harrison, Stephanie R, Campbell, Fiona, Bennett, Hannah, Marco, Gabriele De, Helliwell, Philip S, Golenya, Rebecca, McGonagle, Dennis G, Pardoe, Cleone, Sambi, Pavan, Shams, Kave, Wright, David, Marzo-Ortega, Helena, and Laws, Philip M

Subjects
MEDICAL personnel, ACCESS to primary care, MEDICAL research, PATIENTS' attitudes, CITY dwellers, PSORIATIC arthritis
Abstract

The article published in the British Journal of Dermatology discusses the high prevalence of undiagnosed and undertreated psoriasis in a UK urban population, based on the COPPACA study conducted in Leeds. The study found that delayed diagnosis and treatment of psoriasis can lead to various comorbidities, including psoriatic arthritis, cardiometabolic disease, and anxiety/depression. The research highlights the need for improved diagnosis and treatment of psoriasis in primary care, emphasizing the importance of understanding barriers to healthcare uptake to enhance dermatology services in the community. [Extracted from the article]

Published
2024
Full Text
View/download PDF

5. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis:a cohort study from BADBIR

Author

Alabas, Oras A, Mason, Kaleigh J, Yiu, Zenas Z N, Hampton, Philip J, Reynolds, Nick J, Owen, Caroline M, Bewley, Anthony, Laws, Philip M, Warren, Richard B, Lunt, Mark, Smith, Catherine H, and Griffiths, Christopher E M

Subjects
Dermatology
Abstract

Background Real-world data evaluating effectiveness and persistence of systemic therapies for patients with psoriasis are limited. Objectives To determine the effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters (FAEs) and methotrexate in patients with moderate-to-severe psoriasis. Methods Data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a prospective, multicentre pharmacovigilance register of patients with moderate-to-severe psoriasis receiving biologic and/or conventional systemic therapies, were analysed. Eligible patients were ≥ 16 years of age receiving a first course of acitretin, ciclosporin, FAEs or methotrexate between 2007 and 2021 with ≥ 6 months’ follow-up. Effectiveness was defined as achieving absolute Psoriasis Area and Severity Index (aPASI) ≤ 2 reported ≥ 4 weeks after treatment start date until date of cessation. To identify baseline clinical variables associated with treatment effectiveness, we used multivariable logistic regression models estimating the adjusted odds ratio (aOR) of achieving aPASI ≤ 2. To describe drug persistence associated with ineffectiveness, occurrence of adverse events or other reasons for discontinuation, survival estimates with 95% confidence intervals (CIs) were obtained using a flexible parametric model. Results were obtained using multiple imputed data. Results In total, 5430 patients were included in the analysis. Overall, 1023 (19%) patients were receiving acitretin, 1401 (26%) patients were on ciclosporin, 347 (6%) patients were on FAEs, and 2659 (49%) patients were receiving methotrexate at registration. The proportion of patients who achieved aPASI ≤ 2 was lower for those treated with acitretin [n = 118 (21%)] compared with those receiving ciclosporin [n = 233 (34%)], FAEs [n = 43 (29%)] and methotrexate [n = 372 (32%)]. Factors associated with ineffectiveness included prior experience to previous nonbiologic systemic therapies (acitretin) (aOR 0.64, 95% CI 0.42–0.96), male sex (methotrexate) (aOR 0.58, 95% CI 0.46–0.74), comorbidities (aOR 0.70, 95% CI 0.51–0.97) and alcohol consumption (≤ 14 units per week) (ciclosporin) (aOR 0.70, 95% CI 0.50–0.98). Persistence associated with all reasons for discontinuation showed better survival for methotrexate compared with acitretin, ciclosporin and FAEs cohorts at 12 months [survival estimate 46.1 (95% CI 44.0–48.3), 31.9 (95% CI 29.4–34.7), 30.0 (95% CI 27.5–32.4) and 35.0 (95% CI 29.9–40.9), respectively]. Conclusions The real-world effectiveness and persistence of acitretin, ciclosporin, FAEs and methotrexate were generally low. Previous nonbiologic systemic therapies, male sex, comorbidities and alcohol consumption were risk factors associated with treatment ineffectiveness.

Published
2023
Full Text
View/download PDF

8. Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR

Author

Alabas, Oras A, primary, Mason, Kaleigh J, additional, Yiu, Zenas Z N, additional, Hampton, Philip J, additional, Reynolds, Nick J, additional, Owen, Caroline M, additional, Bewley, Anthony, additional, Laws, Philip M, additional, Warren, Richard B, additional, Lunt, Mark, additional, Smith, Catherine H, additional, and Griffiths, Christopher E M, additional

Published
2023
Full Text
View/download PDF

9. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.

Author

Yusof, Md Yuzaiful Md, Smith, Eve M D, Ainsworth, Sammy, Armon, Kate, Beresford, Michael W, Brown, Morgan, Cherry, Lindsey, Edwards, Christopher J, Flora, Kalveer, Gilman, Rebecca, Griffiths, Bridget, Gordon, Caroline, Howard, Paul, Isenberg, David, Jordan, Natasha, Kaul, Arvind, Lanyon, Peter, Laws, Philip M, Lightsone, Liz, and Lythgoe, Hanna

Subjects
SYSTEMIC lupus erythematosus, RHEUMATOLOGY
Abstract

The objective of this guideline is to provide up-to-date, evidence-based recommendations for the management of SLE that builds upon the existing treatment guideline for adults living with SLE published in 2017. This will incorporate advances in the assessment, diagnosis, monitoring, non-pharmacological and pharmacological management of SLE. General approaches to management as well as organ-specific treatment, including lupus nephritis and cutaneous lupus, will be covered. This will be the first guideline in SLE using a whole life course approach from childhood through adolescence and adulthood. The guideline will be developed with people with SLE as an important target audience in addition to healthcare professionals. It will include guidance related to emerging approved therapies and account for National Institute for Health and Care Excellence Technology Appraisals, National Health Service England clinical commissioning policies and national guidance relevant to SLE. The guideline will be developed using the methods and rigorous processes outlined in 'Creating Clinical Guidelines: Our Protocol' by the British Society for Rheumatology. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Update of the management of chronic psoriasis: new approaches and emerging treatment options

Author

Laws,Philip M, Young,Helen, Laws,Philip M, and Young,Helen

Abstract

Philip M Laws, Helen S YoungThe University of Manchester, Manchester Bioscience and Academic Health Sciences Centre, Department of Dermatology, Salford Royal Hospital (Hope), Manchester, UKAbstract: Psoriasis is a common, chronic inflammatory skin disease which is associated with a number of significant co-morbidities including: impairment of quality of life; cardiovascular disease; and a seronegative arthritis known as psoriatic arthritis. Our understanding of the pathogenesis of psoriasis has developed at a remarkable rate in recent years. These new insights have significantly changed our perception of the condition and have led to the development of several new treatment strategies. Biological agents have proved a major step forward in therapeutic options for psoriasis. The ability to clear, or almost clear, cutaneous disease has changed the outcomes and expectations of many patients with this disease. The impact on both physical and psychological health may be great. This review covers the clinical features and management of psoriasis with specific reference to new therapeutic options.Keywords: psoriasis, management, biological therapy, treatment

Published
2010

22. Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope.

Author

Md Yusof MY, Smith EMD, Ainsworth S, Armon K, Beresford MW, Brown M, Cherry L, Edwards CJ, Flora K, Gilman R, Griffiths B, Gordon C, Howard P, Isenberg D, Jordan N, Kaul A, Lanyon P, Laws PM, Lightsone L, Lythgoe H, Mallen CD, Marks SD, Maxwell N, Moraitis E, Nash C, Pepper RJ, Pilkington C, Psarras A, Rostron H, Skeates J, Skeoch S, Tremarias D, Wincup C, Zoma A, and Vital EM

Abstract

The objective of this guideline is to provide up-to-date, evidence-based recommendations for the management of SLE that builds upon the existing treatment guideline for adults living with SLE published in 2017. This will incorporate advances in the assessment, diagnosis, monitoring, non-pharmacological and pharmacological management of SLE. General approaches to management as well as organ-specific treatment, including lupus nephritis and cutaneous lupus, will be covered. This will be the first guideline in SLE using a whole life course approach from childhood through adolescence and adulthood. The guideline will be developed with people with SLE as an important target audience in addition to healthcare professionals. It will include guidance related to emerging approved therapies and account for National Institute for Health and Care Excellence Technology Appraisals, National Health Service England clinical commissioning policies and national guidance relevant to SLE. The guideline will be developed using the methods and rigorous processes outlined in 'Creating Clinical Guidelines: Our Protocol' by the British Society for Rheumatology., (© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results